All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

palbociclib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
cyclin dependant kinase inhibitors	4941	571190-30-2

Description:

Molecule

Description

Molfile Inchi Smiles Synonyms: palbociclib palbociclib isethionate ibrance PD-0332991 PD-0332991-0054 PF-00080665-73 PD 0332991

Palbociclib is an inhibitor of cyclin-dependent kinases (CDK) 4 and 6. Cyclin D1 and CDK4/6 are downstream of signaling pathways which lead to cellular proliferation. In vitro, palbociclib reduced cellular proliferation of estrogen receptor (ER)-positive breast cancer cell lines by blocking progression of the cell from G1 into S phase of the cell cycle. Treatment of breast cancer cell lines with the combination of palbociclib and antiestrogens leads to decreased retinoblastoma (Rb) protein phosphorylation resulting in reduced E2F expression and signaling, and increased growth arrest compared to treatment with each drug alone. In vitro treatment of ER-positive breast cancer cell lines with the combination of palbociclib and antiestrogens led to increased cell senescence compared to each drug alone, which was sustained for up to 6 days following palbociclib removal and was greater if antiestrogen treatment was continued. In vivo studies using a patient-derived ER-positive breast cancer xenograft model demonstrated that the combination of palbociclib and letrozole increased the inhibition of Rb phosphorylation, downstream signaling, and tumor growth compared to each drug alone. Molecular weight: 447.54 Formula: C24H29N7O2 CLOGP: 2.48 LIPINSKI: 0 HAC: 9 HDO: 2 TPSA: 103.35 ALOGS: -4.41 ROTB: 5 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
94	mg	O

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Nov. 9, 2016	EMA	Pfizer Limited
Feb. 3, 2015	FDA	PFIZER INC
Sept. 27, 2017	PMDA	Pfizer Japan Inc

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neoplasm progression	14159.20	17.16	4594	135097	31834	63317497
White blood cell count decreased	9988.68	17.16	5223	134468	133881	63215450
Fatigue	4972.08	17.16	7726	131965	880302	62469029
Neutropenia	4725.58	17.16	3536	136155	171469	63177862
Full blood count abnormal	1971.14	17.16	1087	138604	30630	63318701
Alopecia	1960.80	17.16	3008	136683	334528	63014803
Neutrophil count decreased	1535.99	17.16	1149	138542	55257	63294074
Full blood count decreased	1305.81	17.16	776	138915	25248	63324083
Nausea	1288.32	17.16	4450	135241	850021	62499310
Hot flush	1227.90	17.16	967	138724	50192	63299139
Stomatitis	1106.91	17.16	1442	138249	137283	63212048
Drug ineffective	1038.51	17.16	506	139185	1044259	62305072
Disease progression	1002.47	17.16	1291	138400	121467	63227864
Red blood cell count decreased	906.26	17.16	736	138955	39909	63309422
Tumour marker increased	860.84	17.16	345	139346	4570	63344761
Decreased appetite	823.23	17.16	1748	137943	249304	63100027
Death	767.13	17.16	2175	137516	372206	62977125
Product dose omission issue	746.72	17.16	1613	138078	232700	63116631
Malignant neoplasm progression	714.76	17.16	892	138799	81229	63268102
Platelet count decreased	589.45	17.16	976	138715	115146	63234185
Constipation	583.20	17.16	1428	138263	223515	63125816
Metastases to bone	575.59	17.16	430	139261	20589	63328742
Dry skin	575.21	17.16	667	139024	56220	63293111
Leukopenia	561.22	17.16	768	138923	76522	63272809
Bone marrow failure	530.88	17.16	471	139220	28819	63320512
Infusion related reaction	512.82	17.16	5	139686	245516	63103815
Bone pain	500.16	17.16	609	139082	54032	63295299
Rheumatoid arthritis	490.27	17.16	15	139676	253804	63095527
Oral pain	479.92	17.16	439	139252	27955	63321376
Diarrhoea	478.95	17.16	2942	136749	712424	62636907
Epistaxis	473.57	17.16	686	139005	72039	63277292
Maternal exposure during pregnancy	452.67	17.16	6	139685	220056	63129275
Contraindicated product administered	451.87	17.16	5	139686	217643	63131688
Systemic lupus erythematosus	416.00	17.16	9	139682	208909	63140422
Second primary malignancy	403.50	17.16	239	139452	7714	63341617
Therapy cessation	366.05	17.16	391	139300	30066	63319265
Therapeutic product effect decreased	353.93	17.16	17	139674	193170	63156161
Asthenia	342.69	17.16	1708	137983	381896	62967435
Drug hypersensitivity	342.25	17.16	128	139563	310559	63038772
Toxicity to various agents	335.42	17.16	68	139623	247182	63102149
Hand deformity	333.99	17.16	3	139688	159454	63189877
Metastases to liver	333.86	17.16	331	139360	23308	63326023
Arthropathy	326.02	17.16	61	139630	234731	63114600
Product dose omission in error	322.84	17.16	204	139487	7408	63341923
Joint swelling	316.71	17.16	163	139528	327503	63021828
Treatment failure	312.57	17.16	36	139655	199007	63150324
Completed suicide	303.86	17.16	3	139688	145670	63203661
Swelling	289.21	17.16	122	139569	275256	63074075
Thrombocytopenia	269.92	17.16	838	138853	150319	63199012
Pericarditis	264.50	17.16	5	139686	131574	63217757
Drug intolerance	263.68	17.16	178	139513	308483	63040848
Neuropathy peripheral	247.93	17.16	677	139014	112990	63236341
Hypersensitivity	235.30	17.16	180	139511	292505	63056826
Wound	233.99	17.16	39	139652	163224	63186107
Breast cancer metastatic	231.22	17.16	200	139491	11818	63337513
Taste disorder	211.09	17.16	201	139490	13461	63335870
Hypotension	206.20	17.16	178	139513	272426	63076905
White blood cell count abnormal	201.17	17.16	141	139550	6101	63343230
Lower respiratory tract infection	190.92	17.16	31	139660	132276	63217055
Intentional product use issue	189.01	17.16	28	139663	127864	63221467
Dysgeusia	188.06	17.16	355	139336	46355	63302976
Psoriatic arthropathy	185.89	17.16	3	139688	91517	63257814
Acute kidney injury	185.02	17.16	184	139507	263231	63086100
Cytopenia	179.84	17.16	171	139520	11430	63337901
Blood test abnormal	179.60	17.16	196	139495	15433	63333898
Onychoclasis	178.61	17.16	131	139560	6091	63343240
Carbohydrate antigen 15-3 increased	177.85	17.16	79	139612	1369	63347962
Discomfort	175.82	17.16	74	139617	167300	63182031
Therapy change	165.52	17.16	124	139567	5957	63343374
Lacrimation increased	161.78	17.16	213	139478	20418	63328913
Injection site pain	161.39	17.16	43	139648	129757	63219574
Asthma	157.20	17.16	43	139648	127518	63221813
Laboratory test abnormal	156.61	17.16	241	139450	26671	63322660
Therapeutic product effect incomplete	148.86	17.16	45	139646	125011	63224320
COVID-19	145.85	17.16	563	139128	112540	63236791
Injection site erythema	144.04	17.16	10	139681	83164	63266167
Overdose	141.41	17.16	39	139652	115039	63234292
Anaemia	136.28	17.16	1107	138584	292323	63057008
Tachycardia	136.21	17.16	45	139646	118111	63231220
Glossodynia	136.13	17.16	116	139575	178760	63170571
Haemoglobin decreased	134.48	17.16	655	139036	144830	63204501
Musculoskeletal stiffness	134.17	17.16	125	139566	184493	63164838
Irritable bowel syndrome	134.17	17.16	13	139678	82399	63266932
PIK3CA-activated mutation	134.01	17.16	59	139632	1000	63348331
Ill-defined disorder	132.83	17.16	13	139678	81742	63267589
Hypertension	128.77	17.16	263	139428	279040	63070291
Osteonecrosis of jaw	126.82	17.16	255	139436	34868	63314463
Mobility decreased	121.81	17.16	57	139634	121102	63228229
Fibromyalgia	120.21	17.16	17	139674	80403	63268928
Cancer pain	118.95	17.16	79	139612	3126	63346205
Madarosis	116.91	17.16	77	139614	3004	63346327
Suicide attempt	116.05	17.16	4	139687	60914	63288417
Cough	111.78	17.16	1058	138633	291685	63057646
Ageusia	111.15	17.16	144	139547	13584	63335747
Hepatic enzyme increased	109.87	17.16	172	139519	202156	63147175
Psoriasis	109.61	17.16	28	139663	86929	63262402
White blood cell disorder	107.67	17.16	68	139623	2466	63346865
Sinusitis	106.50	17.16	211	139480	226442	63122889
Injury	106.00	17.16	17	139674	73230	63276101
Blood cholesterol increased	101.26	17.16	40	139651	93992	63255339
Condition aggravated	100.03	17.16	500	139191	401717	62947614
Adverse event	99.31	17.16	15	139676	67544	63281787
Type 2 diabetes mellitus	99.06	17.16	12	139679	63856	63285475
Confusional state	98.70	17.16	235	139456	236145	63113186
Fall	98.55	17.16	486	139205	391848	62957483
Breast pain	97.04	17.16	108	139583	8690	63340641
Cardiac arrest	97.01	17.16	41	139650	92504	63256827
Myelosuppression	96.44	17.16	181	139510	23522	63325809
Bradycardia	95.38	17.16	22	139669	73205	63276126
Lymphoedema	93.66	17.16	122	139569	11570	63337761
Cardio-respiratory arrest	93.65	17.16	11	139680	59948	63289383
Decreased immune responsiveness	93.13	17.16	81	139610	4820	63344511
Coma	90.78	17.16	16	139675	64348	63284983
Injection site reaction	90.76	17.16	11	139680	58513	63290818
Illness	90.22	17.16	275	139416	48784	63300547
Osteoarthritis	89.61	17.16	49	139642	95294	63254037
Adverse drug reaction	89.02	17.16	32	139659	79682	63269649
Drug interaction	88.51	17.16	237	139454	228894	63120437
Metastases to lung	88.37	17.16	124	139567	12626	63336705
Urticaria	88.06	17.16	143	139548	165659	63183672
Back pain	87.89	17.16	928	138763	263217	63086114
Anaphylactic reaction	87.82	17.16	19	139672	66081	63283250
Oral mucosal blistering	86.01	17.16	83	139608	5650	63343681
Seizure	85.94	17.16	99	139592	132535	63216796
Neoplasm recurrence	83.63	17.16	59	139632	2579	63346752
Medication error	83.15	17.16	9	139682	52275	63297056
Wheezing	83.00	17.16	54	139637	95541	63253790
Metabolic acidosis	82.35	17.16	4	139687	45065	63304266
C-reactive protein increased	81.54	17.16	54	139637	94653	63254678
Hepatic lesion	80.32	17.16	74	139617	4751	63344580
Knee arthroplasty	79.75	17.16	12	139679	54194	63295137
Immune system disorder	79.37	17.16	103	139588	9731	63339600
Injection site pruritus	79.36	17.16	5	139686	45111	63304220
Nail disorder	79.18	17.16	119	139572	12896	63336435
Suicidal ideation	76.95	17.16	21	139670	62400	63286931
Off label use	76.41	17.16	1036	138655	673426	62675905
Depressed level of consciousness	76.31	17.16	21	139670	62057	63287274
Flatulence	75.87	17.16	207	139484	34495	63314836
Syncope	75.63	17.16	88	139603	117297	63232034
Oxygen saturation decreased	71.67	17.16	54	139637	88531	63260800
Respiratory failure	71.58	17.16	71	139620	101787	63247544
Hyponatraemia	70.90	17.16	85	139606	111815	63237516
Nasal dryness	70.00	17.16	67	139624	4514	63344817
Gingival pain	69.83	17.16	88	139603	8074	63341257
Body surface area increased	69.49	17.16	17	139674	31	63349300
Incorrect dose administered	67.08	17.16	24	139667	59944	63289387
Sedation	66.22	17.16	5	139686	38804	63310527
Pleural effusion	65.87	17.16	390	139301	92820	63256511
Blood pressure increased	65.33	17.16	164	139527	161898	63187433
Memory impairment	64.76	17.16	422	139269	103836	63245495
Hip arthroplasty	64.73	17.16	13	139678	47633	63301698
Hypoglycaemia	63.92	17.16	26	139665	60039	63289292
Gastrointestinal haemorrhage	63.74	17.16	51	139640	81125	63268206
Tumour marker abnormal	63.74	17.16	26	139665	361	63348970
Therapeutic response decreased	63.29	17.16	28	139663	61497	63287834
Plasma cell myeloma	63.09	17.16	4	139687	35901	63313430
Flushing	63.05	17.16	44	139647	75043	63274288
Gastrointestinal disorder	62.61	17.16	121	139570	131118	63218213
Bursitis	62.56	17.16	5	139686	37036	63312295
Cardiac failure congestive	62.05	17.16	67	139624	92366	63256965
Oedema peripheral	61.72	17.16	212	139479	189299	63160032
Multiple organ dysfunction syndrome	61.32	17.16	24	139667	56728	63292603
Blood pressure systolic increased	60.23	17.16	15	139676	47382	63301949
Product quality issue	60.14	17.16	5	139686	35860	63313471
Carbohydrate antigen 27.29 increased	59.62	17.16	16	139675	49	63349282
Angioedema	59.38	17.16	16	139675	47949	63301382
Respiratory arrest	59.32	17.16	3	139688	32642	63316689
Injection site swelling	58.65	17.16	16	139675	47556	63301775
Pneumonia	58.57	17.16	683	139008	456084	62893247
Pancytopenia	58.17	17.16	389	139302	96544	63252787
Oedema	57.85	17.16	78	139613	97544	63251787
Septic shock	57.34	17.16	38	139653	66591	63282740
Liver injury	57.01	17.16	31	139660	60489	63288842
Encephalopathy	55.79	17.16	9	139682	38611	63310720
Musculoskeletal chest pain	55.63	17.16	135	139556	20948	63328383
Hypokalaemia	55.59	17.16	89	139602	103715	63245616
Hair texture abnormal	55.47	17.16	57	139634	4186	63345145
Pulmonary hypertension	55.11	17.16	8	139683	37115	63312216
Erythema	54.30	17.16	201	139490	175550	63173781
Hypoacusis	53.73	17.16	145	139546	24006	63325325
Inflammation	52.64	17.16	62	139629	82211	63267120
Skin exfoliation	52.63	17.16	211	139480	42891	63306440
Inappropriate schedule of product administration	52.11	17.16	93	139598	103872	63245459
Metastases to pleura	51.53	17.16	36	139655	1549	63347782
Body surface area decreased	51.33	17.16	12	139679	16	63349315
Palpitations	51.20	17.16	107	139584	112663	63236668
Lactic acidosis	50.87	17.16	11	139680	38276	63311055
Obesity	50.71	17.16	4	139687	29948	63319383
Coronary artery disease	50.41	17.16	6	139685	32371	63316960
Loss of consciousness	50.39	17.16	116	139575	118005	63231326
Unevaluable event	50.36	17.16	25	139666	51361	63297970
Impaired healing	50.26	17.16	93	139598	102449	63246882
Prescribed underdose	50.16	17.16	4	139687	29685	63319646
Injection site bruising	49.99	17.16	15	139676	41895	63307436
Dizziness	49.86	17.16	1268	138423	428657	62920674
International normalised ratio increased	49.56	17.16	20	139671	46405	63302926
Blister	49.54	17.16	135	139556	129679	63219652
Prescribed overdose	49.24	17.16	8	139683	34145	63315186
Haematotoxicity	49.07	17.16	80	139611	9296	63340035
Delirium	48.92	17.16	25	139666	50516	63298815
Rhinorrhoea	48.67	17.16	278	139413	65299	63284032
Unresponsive to stimuli	48.58	17.16	8	139683	33808	63315523
Dyspepsia	47.54	17.16	386	139305	101810	63247521
Malignant pleural effusion	47.37	17.16	42	139649	2564	63346767
Metastases to lymph nodes	47.37	17.16	73	139618	8085	63341246
Orthostatic hypotension	46.81	17.16	11	139680	36149	63313182
Metastases to spine	46.79	17.16	46	139645	3203	63346128
Foot deformity	46.38	17.16	4	139687	27849	63321482
Sleep apnoea syndrome	46.36	17.16	5	139686	29128	63320203
Dysarthria	46.25	17.16	18	139673	42693	63306638
Abdominal pain	46.11	17.16	418	139273	293038	63056293
Pneumonia aspiration	45.73	17.16	10	139681	34530	63314801
Dry mouth	45.23	17.16	310	139381	77553	63271778
Pulmonary thrombosis	45.20	17.16	74	139617	8628	63340703
Hyperkalaemia	45.19	17.16	32	139659	54171	63295160
Agitation	45.11	17.16	39	139652	59718	63289613
Drug withdrawal syndrome	45.02	17.16	4	139687	27190	63322141
Psychotic disorder	44.77	17.16	3	139688	25709	63323622
Metastases to kidney	44.06	17.16	17	139674	202	63349129
Feeling cold	43.99	17.16	134	139557	23754	63325577
Heart rate increased	43.98	17.16	88	139603	94150	63255181
Ascites	43.96	17.16	192	139499	40536	63308795
Altered state of consciousness	43.77	17.16	3	139688	25227	63324104
Neutrophil count abnormal	43.63	17.16	42	139649	2850	63346481
Hallucination	43.59	17.16	34	139657	54783	63294548
Nail growth abnormal	43.21	17.16	22	139669	523	63348808
Oropharyngeal pain	42.93	17.16	355	139336	94132	63255199
Atrial fibrillation	42.50	17.16	124	139567	116512	63232819
Leukocytosis	42.44	17.16	4	139687	25931	63323400
Weight increased	42.05	17.16	369	139322	260423	63088908
Heart rate decreased	41.96	17.16	24	139667	45536	63303795
Injection site haemorrhage	41.86	17.16	3	139688	24311	63325020
Haematuria	41.66	17.16	7	139684	29150	63320181
Carcinoembryonic antigen increased	41.50	17.16	33	139658	1732	63347599
Angina pectoris	41.29	17.16	8	139683	30070	63319261
Spinal pain	41.13	17.16	90	139601	13049	63336282
Pneumonitis	41.07	17.16	170	139521	35052	63314279
Product dispensing error	41.05	17.16	78	139613	10227	63339104
Hair growth abnormal	40.71	17.16	41	139650	2940	63346391
Therapy non-responder	40.70	17.16	65	139626	75836	63273495
Blood pressure fluctuation	40.41	17.16	26	139665	46291	63303040
Appetite disorder	40.41	17.16	64	139627	7257	63342074
Emotional distress	40.02	17.16	11	139680	32538	63316793
Blood creatine phosphokinase increased	39.90	17.16	9	139682	30421	63318910
Product packaging difficult to open	39.87	17.16	13	139678	90	63349241
Pancreatitis	39.55	17.16	30	139661	49025	63300306
Drug dependence	39.48	17.16	4	139687	24479	63324852
Drug ineffective for unapproved indication	39.19	17.16	13	139678	34050	63315281
Eating disorder	38.19	17.16	110	139581	18906	63330425
Pseudocirrhosis	37.84	17.16	22	139669	685	63348646
Metastases to retroperitoneum	37.58	17.16	14	139677	150	63349181
Vomiting	37.53	17.16	1546	138145	558071	62791260
Aggression	37.47	17.16	4	139687	23494	63325837
Breast cancer recurrent	37.45	17.16	47	139644	4294	63345037
Acute myocardial infarction	37.41	17.16	12	139679	32112	63317219
Respiratory distress	37.27	17.16	14	139677	33937	63315394
Myocardial infarction	37.27	17.16	105	139586	99788	63249543
Dysphagia	36.65	17.16	326	139365	88259	63261072
Body temperature increased	36.59	17.16	18	139673	37174	63312157
Joint range of motion decreased	36.23	17.16	13	139678	32415	63316916
Hypoxia	36.21	17.16	47	139644	59745	63289586
Tremor	35.94	17.16	159	139532	132080	63217251
Blood pressure diastolic decreased	35.87	17.16	4	139687	22702	63326629
Stevens-Johnson syndrome	35.62	17.16	6	139685	24944	63324387
Mucosal inflammation	35.51	17.16	200	139491	46728	63302603
Basal cell carcinoma	35.29	17.16	9	139682	27982	63321349
Rash maculo-papular	35.27	17.16	13	139678	31883	63317448
Grip strength decreased	35.02	17.16	4	139687	22283	63327048
Cytomegalovirus infection	34.91	17.16	3	139688	20949	63328382
Chest pain	34.60	17.16	306	139385	215653	63133678
Infection	34.44	17.16	330	139361	228843	63120488
Dry eye	34.42	17.16	179	139512	40582	63308749
Bone cancer	33.99	17.16	27	139664	1415	63347916
Dyskinesia	33.81	17.16	14	139677	31988	63317343
Faeces soft	33.14	17.16	51	139640	5641	63343690
Granulocyte count decreased	33.11	17.16	25	139666	1215	63348116
Anaphylactic shock	33.05	17.16	6	139685	23627	63325704
Wrong technique in product usage process	32.85	17.16	54	139637	62286	63287045
Nasal discomfort	32.55	17.16	46	139645	4714	63344617
Mental status changes	32.20	17.16	24	139667	39575	63309756
Sinus tachycardia	32.18	17.16	7	139684	24261	63325070
Mitral valve incompetence	32.12	17.16	3	139688	19591	63329740
Thrombosis	31.97	17.16	248	139443	64507	63284824
Weight decreased	31.91	17.16	816	138875	275982	63073349
Hypomagnesaemia	31.30	17.16	12	139679	28725	63320606
Proteinuria	31.20	17.16	3	139688	19142	63330189
Adnexa uteri mass	31.12	17.16	18	139673	555	63348776
Metastases to skin	30.62	17.16	27	139664	1636	63347695
Joint dislocation	30.50	17.16	3	139688	18797	63330534
Ventricular tachycardia	30.38	17.16	4	139687	19975	63329356
Hemiparesis	30.30	17.16	7	139684	23275	63326056
Hair disorder	30.30	17.16	23	139668	1127	63348204
Metastases to bladder	30.15	17.16	13	139678	209	63349122
Pallor	29.76	17.16	15	139676	30553	63318778
Diabetic ketoacidosis	29.12	17.16	5	139686	20500	63328831
Incorrect route of product administration	29.02	17.16	12	139679	27440	63321891
Cardiac failure	28.80	17.16	100	139591	89042	63260289
Staphylococcal infection	28.70	17.16	29	139662	41227	63308104
Adrenal insufficiency	28.70	17.16	3	139688	17912	63331419
Hypercholesterolaemia	28.60	17.16	6	139685	21328	63328003
Multiple sclerosis	28.57	17.16	9	139682	24363	63324968
Haematoma	28.44	17.16	21	139670	34799	63314532
Loss of personal independence in daily activities	28.27	17.16	114	139577	97176	63252155
General physical health deterioration	28.18	17.16	295	139396	201107	63148224
Trichorrhexis	27.98	17.16	23	139668	1266	63348065
Tachypnoea	27.45	17.16	3	139688	17299	63332032
Obstructive airways disorder	27.39	17.16	6	139685	20693	63328638
Drug level increased	27.37	17.16	8	139683	22728	63326603
Insomnia	27.32	17.16	643	139048	214609	63134722
Chronic kidney disease	27.16	17.16	36	139655	45362	63303969
Vasculitis	26.85	17.16	4	139687	18205	63331126
Red blood cell count abnormal	26.73	17.16	21	139670	1083	63348248
Melaena	26.55	17.16	17	139674	30348	63318983
Arrhythmia	26.31	17.16	27	139664	38113	63311218
Urine odour abnormal	26.25	17.16	49	139642	6340	63342991
Device malfunction	26.16	17.16	4	139687	17853	63331478
Hypervolaemia	26.11	17.16	15	139676	28398	63320933
Parosmia	26.00	17.16	48	139643	6158	63343173
Toothache	25.89	17.16	97	139594	19102	63330229
Injection site rash	25.82	17.16	5	139686	18804	63330527
Increased appetite	25.76	17.16	62	139629	9568	63339763
Swelling face	25.74	17.16	64	139627	63411	63285920
Aphthous ulcer	25.49	17.16	78	139613	13860	63335471
Radiation injury	25.43	17.16	15	139676	480	63348851
Poor quality product administered	25.38	17.16	33	139658	3123	63346208
Drug eruption	25.18	17.16	16	139675	28678	63320653
Arthritis	24.94	17.16	151	139540	115770	63233561
Prehypertension	24.65	17.16	7	139684	28	63349303
Joint effusion	24.58	17.16	4	139687	17056	63332275
Cardiogenic shock	24.13	17.16	5	139686	17927	63331404
Metastasis	24.08	17.16	42	139649	5155	63344176
Skin ulcer	23.90	17.16	36	139655	43009	63306322
Eructation	23.76	17.16	55	139636	8278	63341053
Night sweats	23.57	17.16	186	139505	48628	63300703
Muscle twitching	23.53	17.16	7	139684	19661	63329670
Abnormal behaviour	23.24	17.16	9	139682	21417	63327914
Osteoporosis	23.10	17.16	58	139633	57280	63292051
Treatment noncompliance	22.95	17.16	29	139662	37296	63312035
No adverse event	22.63	17.16	35	139656	41370	63307961
Chronic obstructive pulmonary disease	22.57	17.16	67	139624	62619	63286712
Transient ischaemic attack	22.52	17.16	30	139661	37723	63311608
Ovarian cyst	22.40	17.16	4	139687	15941	63333390
Ovarian disorder	22.39	17.16	16	139675	714	63348617
Foreign body in throat	22.39	17.16	12	139679	318	63349013
Macular degeneration	22.22	17.16	13	139678	24363	63324968
Shock	22.12	17.16	12	139679	23451	63325880
Pulmonary arterial hypertension	22.10	17.16	11	139680	22566	63326765
Upper gastrointestinal haemorrhage	22.03	17.16	7	139684	18845	63330486
Intervertebral disc degeneration	21.99	17.16	4	139687	15728	63333603
Myalgia	21.85	17.16	448	139243	146081	63203250
Metastases to adrenals	21.71	17.16	16	139675	749	63348582
Metastases to peritoneum	21.69	17.16	32	139659	3410	63345921
Coagulopathy	21.68	17.16	9	139682	20535	63328796
Tendonitis	21.68	17.16	8	139683	19607	63329724
Ear infection	21.18	17.16	32	139659	38181	63311150
Lip pain	21.15	17.16	23	139668	1803	63347528
Lupus-like syndrome	21.14	17.16	4	139687	15291	63334040
Pleural neoplasm	21.07	17.16	12	139679	359	63348972
Arthralgia	21.06	17.16	1489	138202	568221	62781110
Circulatory collapse	21.01	17.16	11	139680	21927	63327404
Road traffic accident	20.96	17.16	30	139661	36602	63312729
Infusion site coldness	20.94	17.16	10	139681	206	63349125
Hypersomnia	20.93	17.16	87	139604	17968	63331363
Mean cell volume increased	20.93	17.16	32	139659	3519	63345812
Acute respiratory distress syndrome	20.82	17.16	13	139678	23521	63325810
Autoimmune disorder	20.76	17.16	6	139685	17171	63332160
Artificial menopause	20.74	17.16	6	139685	26	63349305
Hypothyroidism	20.59	17.16	39	139652	42593	63306738
Eastern Cooperative Oncology Group performance status worsened	20.42	17.16	19	139672	1235	63348096
Respiratory depression	20.25	17.16	3	139688	13712	63335619
Exostosis	20.23	17.16	7	139684	17855	63331476
Feeding disorder	20.13	17.16	70	139621	13292	63336039
Tongue blistering	20.08	17.16	21	139670	1574	63347757
Tumour pain	20.06	17.16	20	139671	1417	63347914
Neuroendocrine breast tumour	20.04	17.16	6	139685	30	63349301
Noninfective gingivitis	20.01	17.16	20	139671	1421	63347910
Liver function test abnormal	19.99	17.16	48	139643	48133	63301198
Tongue discomfort	19.97	17.16	25	139666	2278	63347053
Sepsis	19.92	17.16	228	139463	152895	63196436
Pain	19.89	17.16	1383	138308	739245	62610086
Gingival bleeding	19.89	17.16	67	139624	12520	63336811
Joint neoplasm	19.87	17.16	7	139684	63	63349268
Hepatitis	19.56	17.16	36	139655	39752	63309579
Peripheral venous disease	19.46	17.16	5	139686	15472	63333859
Hypogeusia	19.46	17.16	19	139672	1312	63348019
Underdose	19.44	17.16	19	139672	27437	63321894
Hypoaesthesia	19.25	17.16	496	139195	167897	63181434
Bronchospasm	19.18	17.16	7	139684	17273	63332058
Hypertensive crisis	19.11	17.16	5	139686	15281	63334050
Soft tissue neoplasm	19.04	17.16	7	139684	72	63349259
Feeling abnormal	19.03	17.16	444	139247	147948	63201383
Pyrexia	18.98	17.16	844	138847	469634	62879697
Product substitution issue	18.58	17.16	6	139685	15990	63333341
Myocardial ischaemia	18.56	17.16	3	139688	12856	63336475
Cyanosis	18.56	17.16	7	139684	16928	63332403
Product use complaint	18.56	17.16	25	139666	2449	63346882
Migraine	18.56	17.16	142	139549	103204	63246127
Osteonecrosis	18.52	17.16	16	139675	24514	63324817
Blood pressure decreased	18.38	17.16	77	139614	64945	63284386
Tongue disorder	18.23	17.16	58	139633	10522	63338809
Urinary retention	18.16	17.16	24	139667	30277	63319054
Face oedema	18.11	17.16	11	139680	20201	63329130
Dental discomfort	18.11	17.16	12	139679	473	63348858
Acute respiratory failure	18.05	17.16	30	139661	34455	63314876
Metastases to the mediastinum	18.04	17.16	12	139679	476	63348855
Hallucination, visual	18.00	17.16	10	139681	19288	63330043
Uveitis	17.96	17.16	3	139688	12550	63336781
Nail discolouration	17.96	17.16	26	139665	2724	63346607
Mastectomy	17.93	17.16	20	139671	1613	63347718
Acute cutaneous lupus erythematosus	17.84	17.16	10	139681	290	63349041
Femur fracture	17.80	17.16	41	139650	41715	63307616
Breast cancer female	17.80	17.16	4	139687	13555	63335776
Mania	17.60	17.16	3	139688	12364	63336967
Haemorrhage intracranial	17.53	17.16	4	139687	13415	63335916
Skin sensitisation	17.51	17.16	15	139676	874	63348457
Clostridium difficile colitis	17.33	17.16	12	139679	20557	63328774
Cholelithiasis	17.26	17.16	45	139646	43880	63305451
Gamma-glutamyltransferase decreased	17.24	17.16	10	139681	310	63349021
Product packaging issue	17.23	17.16	17	139674	1189	63348142
Spinal osteoarthritis	17.23	17.16	7	139684	16179	63333152

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product use issue	537.45	32.45	199	2687	63017	34891028
Neoplasm progression	487.30	32.45	145	2741	23155	34930890
Fatigue	145.10	32.45	164	2722	370489	34583556
Product use in unapproved indication	139.72	32.45	98	2788	117401	34836644
Off label use	127.04	32.45	163	2723	419361	34534684
White blood cell count decreased	111.87	32.45	79	2807	95366	34858679
Hydrocephalus	57.20	32.45	20	2866	5212	34948833
Neutropenia	53.32	32.45	65	2821	156713	34797332
Hot flush	52.80	32.45	27	2859	18039	34936006
Death	50.75	32.45	105	2781	397944	34556101
Xerosis	43.08	32.45	10	2876	594	34953451

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neoplasm progression	13134.13	17.99	4408	127345	47274	79565361
White blood cell count decreased	9566.54	17.99	5101	126652	183187	79429448
Fatigue	6116.32	17.99	7530	124223	922197	78690438
Alopecia	3346.35	17.99	2882	128871	228473	79384162
Neutropenia	3064.02	17.99	3020	128733	284690	79327945
Full blood count abnormal	1931.37	17.99	1057	130696	39417	79573218
Nausea	1592.83	17.99	4282	127471	952914	78659721
Full blood count decreased	1398.04	17.99	743	131010	26076	79586559
Hot flush	1391.80	17.99	957	130796	53920	79558715
Stomatitis	1265.42	17.99	1379	130374	145378	79467257
Neutrophil count decreased	1202.74	17.99	1095	130658	92864	79519771
Product dose omission issue	1007.96	17.99	1608	130145	245929	79366706
Tumour marker increased	888.91	17.99	315	131438	3957	79608678
Red blood cell count decreased	838.67	17.99	722	131031	56791	79555844
Drug ineffective	811.49	17.99	389	131364	1080524	78532111
Decreased appetite	760.02	17.99	1717	130036	340701	79271934
Dry skin	616.83	17.99	657	131096	67338	79545297
Constipation	607.18	17.99	1401	130352	281649	79330986
Disease progression	598.96	17.99	1084	130669	183278	79429357
Bone pain	549.22	17.99	563	131190	55179	79557456
Oral pain	541.85	17.99	437	131316	31361	79581274
Diarrhoea	515.93	17.99	2831	128922	877658	78734977
Toxicity to various agents	483.61	17.99	63	131690	421477	79191158
Death	416.01	17.99	1943	129810	564571	79048064
Acute kidney injury	413.11	17.99	171	131582	519233	79093402
Platelet count decreased	409.70	17.99	957	130796	193707	79418928
Epistaxis	385.31	17.99	674	131079	110841	79501794
Product dose omission in error	383.85	17.99	208	131545	7580	79605055
Infusion related reaction	354.27	17.99	5	131748	230232	79382403
Leukopenia	346.54	17.99	660	131093	115853	79496782
Bone marrow failure	345.09	17.99	424	131329	50683	79561952
Metastases to bone	326.46	17.99	292	131461	24135	79588500
Asthenia	319.01	17.99	1676	130077	510013	79102622
Second primary malignancy	302.92	17.99	224	131529	14126	79598509
Hypotension	294.44	17.99	182	131571	440135	79172500
Rheumatoid arthritis	289.25	17.99	13	131740	208457	79404178
Therapy cessation	287.11	17.99	332	131421	37230	79575405
Drug hypersensitivity	236.35	17.99	99	131654	298817	79313818
Contraindicated product administered	235.77	17.99	5	131748	157533	79455102
White blood cell count abnormal	235.62	17.99	136	131617	5609	79607026
Neuropathy peripheral	230.46	17.99	631	131122	140674	79471961
Taste disorder	229.15	17.99	198	131555	15625	79597010
Therapeutic product effect decreased	218.52	17.99	13	131740	163850	79448785
Drug interaction	216.61	17.99	220	131533	414963	79197672
Onychoclasis	215.42	17.99	127	131626	5451	79607184
Maternal exposure during pregnancy	209.82	17.99	3	131750	136535	79476100
Dysgeusia	209.70	17.99	355	131398	56822	79555813
Laboratory test abnormal	206.15	17.99	243	131510	27805	79584830
Blood test abnormal	200.45	17.99	193	131560	17517	79595118
Lacrimation increased	199.81	17.99	215	131538	22262	79590373
Overdose	198.31	17.99	33	131720	184173	79428462
Carbohydrate antigen 15-3 increased	186.28	17.99	71	131682	1108	79611527
Treatment failure	178.15	17.99	33	131720	170453	79442182
Tachycardia	174.20	17.99	40	131713	177728	79434907
Cardiac arrest	174.17	17.99	36	131717	172060	79440575
Intentional product use issue	173.52	17.99	23	131730	152089	79460546
Systemic lupus erythematosus	173.26	17.99	6	131747	121143	79491492
Metastases to liver	169.04	17.99	221	131532	28093	79584542
Breast cancer metastatic	165.40	17.99	127	131626	8475	79604160
Hand deformity	156.66	17.99	3	131750	103916	79508719
Malignant neoplasm progression	152.47	17.99	533	131220	135457	79477178
Pericarditis	149.63	17.99	5	131748	104231	79508404
Drug intolerance	148.10	17.99	131	131622	263988	79348647
Illness	147.54	17.99	271	131482	46240	79566395
Joint swelling	144.74	17.99	158	131595	288488	79324147
Bradycardia	144.30	17.99	25	131728	135532	79477103
Therapy change	139.56	17.99	108	131645	7291	79605344
Cardio-respiratory arrest	137.69	17.99	11	131742	108499	79504136
Arthropathy	134.62	17.99	62	131691	177049	79435586
Respiratory failure	133.42	17.99	66	131687	180845	79431790
Gastrointestinal haemorrhage	131.88	17.99	40	131713	147679	79464956
Madarosis	127.49	17.99	71	131682	2731	79609904
Multiple organ dysfunction syndrome	126.20	17.99	23	131730	120223	79492412
COVID-19	124.09	17.99	553	131200	157121	79455514
Therapeutic product effect incomplete	123.51	17.99	40	131713	141605	79471030
Back pain	123.50	17.99	893	130860	303287	79309348
Cough	122.50	17.99	1029	130724	365760	79246875
Metabolic acidosis	121.97	17.99	3	131750	82526	79530109
Pneumonia	116.91	17.99	628	131125	659618	78953017
Breast pain	116.79	17.99	102	131651	8163	79604472
Suicide attempt	115.53	17.99	5	131748	82927	79529708
Psoriatic arthropathy	114.65	17.99	3	131750	77996	79534639
Lymphoedema	114.32	17.99	121	131632	12292	79600343
Asthma	112.85	17.99	41	131712	135054	79477581
Hypersensitivity	112.18	17.99	162	131591	262077	79350558
Lower respiratory tract infection	111.77	17.99	37	131716	129183	79483452
Injection site pain	110.87	17.99	38	131715	129800	79482835
Product use issue	110.71	17.99	658	131095	209164	79403471
Ageusia	110.62	17.99	137	131616	16495	79596140
Coma	110.61	17.99	17	131736	100632	79512003
Arthralgia	109.67	17.99	1433	130320	570370	79042265
Hyperkalaemia	109.57	17.99	27	131726	114371	79498264
Memory impairment	108.43	17.99	418	131335	111316	79501319
Decreased immune responsiveness	107.83	17.99	82	131671	5393	79607242
Hyponatraemia	107.35	17.99	82	131671	177766	79434869
Depressed level of consciousness	106.96	17.99	16	131737	96636	79515999
Seizure	106.61	17.99	93	131660	188741	79423894
Septic shock	106.49	17.99	35	131718	122766	79489869
Hypertension	106.30	17.99	244	131509	330748	79281887
Confusional state	105.73	17.99	230	131523	317767	79294868
Syncope	105.46	17.99	85	131668	179364	79433271
Swelling	103.84	17.99	123	131630	216588	79396047
White blood cell disorder	103.54	17.99	65	131688	3127	79609508
Nail disorder	101.19	17.99	111	131642	11741	79600894
Oral mucosal blistering	96.18	17.99	81	131672	6170	79606465
Hypoglycaemia	95.33	17.99	25	131728	101569	79511066
Atrial fibrillation	94.07	17.99	113	131640	197773	79414862
C-reactive protein increased	93.72	17.99	48	131705	128979	79483656
Injection site erythema	93.66	17.99	10	131743	78187	79534448
Cytopenia	93.20	17.99	140	131613	20243	79592392
Wound	92.49	17.99	38	131715	116141	79496494
Cardiac failure congestive	92.05	17.99	61	131692	142341	79470294
Cancer pain	91.25	17.99	73	131680	5172	79607463
Fall	91.16	17.99	455	131298	487174	79125461
Oxygen saturation decreased	87.94	17.99	52	131701	128995	79483640
Condition aggravated	87.28	17.99	479	131274	500645	79111990
Blood pressure systolic increased	87.23	17.99	6	131747	66980	79545655
Acute myocardial infarction	86.99	17.99	12	131741	77024	79535611
Myocardial infarction	86.61	17.99	106	131647	184023	79428612
Haemoglobin decreased	86.02	17.99	645	131108	221474	79391161
Dyspepsia	85.32	17.99	381	131372	108306	79504329
International normalised ratio increased	85.11	17.99	18	131735	84703	79527932
Flatulence	84.22	17.99	205	131548	42519	79570116
Anaphylactic reaction	83.70	17.99	18	131735	83725	79528910
Angioedema	83.18	17.99	13	131740	76022	79536613
Delirium	82.95	17.99	19	131734	84608	79528027
Thrombocytopenia	82.08	17.99	732	131021	264527	79348108
Coronary artery disease	82.05	17.99	7	131746	65467	79547168
Lactic acidosis	81.76	17.99	10	131743	70349	79542286
Respiratory arrest	81.75	17.99	3	131750	57547	79555088
Medication error	81.65	17.99	9	131744	68633	79544002
Nasal dryness	80.43	17.99	64	131689	4499	79608136
Sepsis	79.87	17.99	207	131546	269221	79343414
Gingival pain	79.84	17.99	86	131667	8912	79603723
Haematuria	79.46	17.99	10	131743	68826	79543809
Injury	78.81	17.99	16	131737	77480	79535155
Cardiac failure	78.39	17.99	84	131669	154758	79457877
Osteonecrosis of jaw	77.44	17.99	200	131553	43026	79569609
Encephalopathy	77.29	17.99	10	131743	67387	79545248
Psoriasis	76.85	17.99	26	131727	89561	79523074
Pneumonia aspiration	76.64	17.99	10	131743	66957	79545678
Oedema peripheral	75.41	17.99	193	131560	252095	79360540
Hair texture abnormal	74.20	17.99	55	131698	3479	79609156
Mobility decreased	74.13	17.99	56	131697	122119	79490516
Immune system disorder	73.59	17.99	91	131662	10938	79601697
Ill-defined disorder	72.66	17.99	11	131742	65864	79546771
Blood pressure increased	70.92	17.99	152	131601	211208	79401427
Blood creatine phosphokinase increased	70.73	17.99	12	131741	66078	79546557
Wheezing	70.11	17.99	54	131699	116610	79496025
Tumour marker abnormal	70.09	17.99	24	131729	270	79612365
Agitation	69.62	17.99	39	131714	99676	79512959
Dry mouth	69.42	17.99	309	131444	87710	79524925
Plasma cell myeloma	68.68	17.99	5	131748	53254	79559381
Neoplasm recurrence	67.72	17.99	56	131697	4158	79608477
Suicidal ideation	67.52	17.99	21	131732	76319	79536316
Anaemia	66.77	17.99	1069	130684	443946	79168689
Loss of consciousness	65.80	17.99	110	131643	167833	79444802
Musculoskeletal stiffness	65.50	17.99	118	131635	174890	79437745
Hallucination	65.15	17.99	30	131723	85715	79526920
Irritable bowel syndrome	65.09	17.99	12	131741	62229	79550406
Oropharyngeal pain	64.89	17.99	354	131399	108999	79503636
Incorrect dose administered	64.42	17.99	23	131730	76607	79536028
Sedation	63.81	17.99	6	131747	51889	79560746
Discomfort	63.74	17.99	68	131685	125549	79487086
Myelosuppression	63.67	17.99	178	131575	40118	79572517
Hypokalaemia	63.52	17.99	87	131666	143953	79468682
Orthostatic hypotension	62.82	17.99	9	131744	56155	79556480
Aggression	62.37	17.99	6	131747	50952	79561683
Dry eye	62.20	17.99	167	131586	36764	79575871
Adverse event	62.13	17.99	12	131741	60202	79552433
Dizziness	62.04	17.99	1217	130536	525224	79087411
Type 2 diabetes mellitus	61.96	17.99	10	131743	57112	79555523
Rhinorrhoea	61.45	17.99	269	131484	75805	79536830
Abdominal discomfort	61.42	17.99	659	131094	250068	79362567
Carbohydrate antigen 27.29 increased	60.39	17.99	15	131738	45	79612590
Insomnia	60.34	17.99	645	131108	244525	79368110
Unresponsive to stimuli	59.99	17.99	10	131743	55778	79556857
Urticaria	59.82	17.99	136	131617	185065	79427570
PIK3CA-activated mutation	59.81	17.99	26	131727	577	79612058
Hypoxia	59.27	17.99	50	131703	103193	79509442
Dysarthria	59.10	17.99	19	131734	67603	79545032
Hypoacusis	58.71	17.99	144	131609	30006	79582629
Angina pectoris	58.54	17.99	8	131745	51724	79560911
Injection site reaction	58.51	17.99	10	131743	54775	79557860
Cytomegalovirus infection	58.00	17.99	3	131750	42641	79569994
Febrile neutropenia	57.88	17.99	192	131561	230807	79381828
Injection site pruritus	57.43	17.99	3	131750	42280	79570355
Vomiting	57.02	17.99	1471	130282	664357	78948278
Altered state of consciousness	56.84	17.99	4	131749	43818	79568817
Fibromyalgia	56.37	17.99	18	131735	64322	79548313
Renal failure	56.07	17.99	159	131594	200809	79411826
Psychotic disorder	56.04	17.99	3	131750	41399	79571236
Musculoskeletal chest pain	55.54	17.99	125	131628	24639	79587996
Pulmonary hypertension	55.45	17.99	7	131746	48073	79564562
Respiratory distress	55.40	17.99	14	131739	58325	79554310
Metastases to lung	55.29	17.99	104	131649	18059	79594576
Body surface area increased	55.02	17.99	17	131736	134	79612501
Heart rate decreased	54.36	17.99	24	131729	70292	79542343
General physical health deterioration	54.14	17.99	252	131501	274986	79337649
Ventricular tachycardia	53.89	17.99	4	131749	41931	79570704
Cardiogenic shock	53.86	17.99	4	131749	41910	79570725
Melaena	53.40	17.99	17	131736	60873	79551762
Oedema	52.95	17.99	72	131681	119508	79493127
Product packaging difficult to open	52.85	17.99	13	131740	37	79612598
Inappropriate schedule of product administration	52.83	17.99	87	131666	133541	79479094
Blood cholesterol increased	52.57	17.99	37	131716	83683	79528952
Stevens-Johnson syndrome	52.51	17.99	3	131750	39163	79573472
Off label use	52.49	17.99	1122	130631	906093	78706542
Rash maculo-papular	52.22	17.99	14	131739	56064	79556571
Drug dependence	52.08	17.99	4	131749	40765	79571870
Appetite disorder	51.87	17.99	64	131689	7675	79604960
Abdominal pain	51.71	17.99	404	131349	389165	79223470
Pyrexia	51.61	17.99	800	130953	677909	78934726
Flushing	51.60	17.99	42	131711	88226	79524409
Therapeutic response decreased	51.39	17.99	23	131730	66830	79545805
Drug ineffective for unapproved indication	51.23	17.99	11	131742	51227	79561408
Hair growth abnormal	51.12	17.99	40	131713	2744	79609891
Leukocytosis	50.92	17.99	6	131747	43449	79569186
Pancreatitis	50.55	17.99	25	131728	68550	79544085
Hypoaesthesia	49.92	17.99	484	131269	178868	79433767
Erythema	49.71	17.99	195	131558	223095	79389540
Skin exfoliation	49.28	17.99	201	131552	54899	79557736
Therapy non-responder	49.06	17.99	48	131705	92257	79520378
Hepatic lesion	49.00	17.99	59	131694	6900	79605735
Blood pressure fluctuation	48.71	17.99	25	131728	67120	79545515
Mental status changes	48.47	17.99	25	131728	66934	79545701
Feeling cold	48.47	17.99	130	131623	28599	79584036
Adverse drug reaction	47.75	17.99	25	131728	66367	79546268
Hepatic enzyme increased	47.68	17.99	149	131604	182461	79430174
Body surface area decreased	47.59	17.99	12	131741	39	79612596
Eating disorder	47.01	17.99	105	131648	20592	79592043
Product dispensing error	46.82	17.99	81	131672	13182	79599453
Unevaluable event	46.18	17.99	17	131736	55568	79557067
Rhabdomyolysis	45.76	17.99	62	131691	103069	79509566
Spinal pain	45.45	17.99	87	131666	15305	79597330
Sleep apnoea syndrome	45.43	17.99	4	131749	36474	79576161
Circulatory collapse	44.64	17.99	5	131748	37663	79574972
Bursitis	44.45	17.99	4	131749	35840	79576795
Nail growth abnormal	44.41	17.99	20	131733	484	79612151
Feeling abnormal	43.51	17.99	428	131325	158771	79453864
Osteoarthritis	43.47	17.99	48	131705	87261	79525374
Trichorrhexis	43.41	17.99	23	131730	800	79611835
Carcinoembryonic antigen increased	43.32	17.99	33	131720	2176	79610459
Upper gastrointestinal haemorrhage	43.22	17.99	8	131745	41372	79571263
Hypomagnesaemia	43.14	17.99	12	131741	46899	79565736
Drug level increased	42.87	17.99	7	131746	39644	79572991
Drug eruption	42.78	17.99	10	131743	43925	79568710
Drug withdrawal syndrome	42.72	17.99	4	131749	34714	79577921
Arrhythmia	42.71	17.99	24	131729	61248	79551387
Adnexa uteri mass	42.41	17.99	18	131735	376	79612259
Shock	42.23	17.99	10	131743	43538	79569097
Pallor	42.12	17.99	15	131738	50047	79562588
Proteinuria	42.06	17.99	3	131750	32499	79580136
Product quality issue	41.52	17.99	4	131749	33936	79578699
Tachypnoea	41.37	17.99	3	131750	32060	79580575
Heart rate increased	41.16	17.99	86	131667	120638	79491997
Cerebral haemorrhage	41.06	17.99	22	131731	57651	79554984
Obesity	40.79	17.99	5	131748	35120	79577515
Accidental exposure to product	40.22	17.99	3	131750	31319	79581316
Haematoma	40.05	17.99	18	131735	52177	79560458
Injection site swelling	39.86	17.99	14	131739	47118	79565517
Anaphylactic shock	39.72	17.99	6	131747	35990	79576645
Night sweats	39.65	17.99	181	131572	51914	79560721
Diabetic ketoacidosis	39.27	17.99	5	131748	34117	79578518
Acute respiratory failure	39.15	17.99	25	131728	59516	79553119
Emotional distress	39.11	17.99	9	131744	39960	79572675
Neutrophil count abnormal	39.09	17.99	38	131715	3488	79609147
Sinus tachycardia	38.84	17.99	7	131746	36901	79575734
Tremor	38.18	17.99	148	131605	169935	79442700
Prescribed overdose	38.14	17.99	8	131745	37875	79574760
Incorrect route of product administration	38.14	17.99	6	131747	34923	79577712
Abnormal behaviour	38.13	17.99	7	131746	36414	79576221
Knee arthroplasty	38.06	17.99	12	131741	43236	79569399
Nasal discomfort	37.81	17.99	46	131707	5437	79607198
Pulmonary thrombosis	37.43	17.99	70	131683	12101	79600534
Acute respiratory distress syndrome	37.42	17.99	13	131740	44054	79568581
Prescribed underdose	37.41	17.99	3	131750	29511	79583124
Pruritus	37.29	17.99	884	130869	393764	79218871
Dyskinesia	36.68	17.99	14	131739	44759	79567876
Urine odour abnormal	35.95	17.99	48	131705	6225	79606410
Chest pain	35.93	17.99	296	131457	282008	79330627
Pseudocirrhosis	35.86	17.99	19	131734	661	79611974
Blood pressure diastolic decreased	35.83	17.99	4	131749	30212	79582423
Electrocardiogram QT prolonged	35.58	17.99	59	131694	90327	79522308
Hypervolaemia	35.56	17.99	13	131740	42677	79569958
Coagulopathy	35.45	17.99	8	131745	35998	79576637
Basal cell carcinoma	35.43	17.99	9	131744	37366	79575269
Inflammation	35.25	17.99	63	131690	93690	79518945
Injection site haemorrhage	34.86	17.99	3	131750	27867	79584768
Malignant pleural effusion	34.83	17.99	35	131718	3345	79609290
Blood pressure decreased	34.63	17.99	70	131683	99396	79513239
Respiratory depression	34.49	17.99	3	131750	27627	79585008
Hemiparesis	34.22	17.99	7	131746	33726	79578909
Hair disorder	34.10	17.99	22	131731	1110	79611525
Staphylococcal infection	33.74	17.99	28	131725	58267	79554368
Ventricular fibrillation	33.71	17.99	6	131747	31920	79580715
Injection site bruising	33.29	17.99	13	131740	40989	79571646
Withdrawal syndrome	33.29	17.99	3	131750	26851	79585784
Obstructive airways disorder	33.03	17.99	6	131747	31453	79581182
Liver injury	33.01	17.99	27	131726	56587	79556048
Body temperature increased	31.54	17.99	17	131736	44403	79568232
Toothache	31.33	17.99	88	131665	19882	79592753
Thrombosis	31.26	17.99	242	131511	83858	79528777
Tubulointerstitial nephritis	31.25	17.99	12	131741	38223	79574412
Myocardial ischaemia	31.24	17.99	3	131750	25516	79587119
Wrong technique in product usage process	31.19	17.99	46	131707	73829	79538806
Palpitations	31.17	17.99	106	131647	126504	79486131
Pancreatitis acute	31.04	17.99	22	131731	49582	79563053
Disorientation	30.71	17.99	35	131718	62741	79549894
Urinary retention	30.61	17.99	29	131724	56601	79556034
Pleural neoplasm	30.52	17.99	14	131739	354	79612281
Metastases to bladder	30.52	17.99	13	131740	274	79612361
Chronic kidney disease	30.13	17.99	39	131714	66115	79546520
Alanine aminotransferase increased	30.11	17.99	152	131601	162418	79450217
Weight decreased	30.07	17.99	784	130969	354414	79258221
Increased appetite	29.75	17.99	63	131690	11915	79600720
Faeces soft	29.60	17.99	51	131702	8272	79604363
Ovarian disorder	29.57	17.99	15	131738	476	79612159
Prehypertension	29.55	17.99	7	131746	16	79612619
Hyperglycaemia	29.50	17.99	44	131709	70291	79542344
Breast cancer recurrent	29.17	17.99	30	131723	2947	79609688
Treatment noncompliance	29.16	17.99	26	131727	52242	79560393
Granulocyte count decreased	29.00	17.99	24	131729	1784	79610851
Body height decreased	28.48	17.99	51	131702	8529	79604106
Renal tubular necrosis	28.03	17.99	4	131749	25035	79587600
Haemorrhage intracranial	27.49	17.99	5	131748	26188	79586447
Poor quality product administered	27.47	17.99	32	131721	3613	79609022
Hallucination, visual	27.20	17.99	10	131743	32719	79579916
Drug-induced liver injury	27.11	17.99	42	131711	66075	79546560
Haematotoxicity	26.96	17.99	71	131682	15448	79597187
Neurotoxicity	26.92	17.99	10	131743	32508	79580127
Bone cancer	26.77	17.99	24	131729	1988	79610647
Deep vein thrombosis	26.63	17.99	106	131647	120813	79491822
Vulvovaginal dryness	26.61	17.99	25	131728	2199	79610436
Foot deformity	26.59	17.99	4	131749	24070	79588565
Chronic obstructive pulmonary disease	26.54	17.99	64	131689	85355	79527280
Hip arthroplasty	26.40	17.99	13	131740	35743	79576892
Liver function test abnormal	26.39	17.99	41	131712	64434	79548201
Face oedema	26.24	17.99	7	131746	28129	79584506
Transient ischaemic attack	26.20	17.99	29	131724	52666	79559969
Haematochezia	26.19	17.99	67	131686	87578	79525057
Aphthous ulcer	26.08	17.99	74	131679	16815	79595820
Myelodysplastic syndrome	25.63	17.99	9	131744	30292	79582343
Skin ulcer	25.62	17.99	31	131722	54119	79558516
Labelled drug-drug interaction medication error	25.56	17.99	7	131746	27643	79584992
Bronchospasm	25.55	17.99	5	131748	24854	79587781
Headache	25.48	17.99	1322	130431	652450	78960185
Subdural haematoma	25.47	17.99	10	131743	31424	79581211
Rectal haemorrhage	25.46	17.99	55	131698	76245	79536390
Pleural effusion	25.22	17.99	358	131395	144904	79467731
Emotional disorder	25.18	17.99	66	131687	14321	79598314
Device malfunction	25.03	17.99	3	131750	21445	79591190
Osteonecrosis	25.02	17.99	10	131743	31085	79581550
Clostridium difficile colitis	24.98	17.99	11	131742	32272	79580363
Parosmia	24.97	17.99	43	131710	6971	79605664
Restlessness	24.90	17.99	24	131729	46468	79566167
Therapeutic response unexpected	24.81	17.99	81	131672	19865	79592770
Red blood cell count abnormal	24.80	17.99	20	131733	1433	79611202
Diabetes mellitus inadequate control	24.69	17.99	5	131748	24259	79588376
Hypersomnia	24.56	17.99	89	131664	22997	79589638
Hepatic encephalopathy	24.54	17.99	5	131748	24161	79588474
Blood triglycerides increased	24.42	17.99	3	131750	21037	79591598
Nasopharyngitis	24.35	17.99	570	131183	253311	79359324
Mastectomy	24.35	17.99	18	131735	1134	79611501
Product use complaint	24.29	17.99	25	131728	2458	79610177
Accidental overdose	24.18	17.99	18	131735	39563	79573072
Diabetes mellitus	24.15	17.99	59	131694	78331	79534304
Abdominal pain upper	24.14	17.99	511	131242	223308	79389327
Toxic skin eruption	23.96	17.99	4	131749	22289	79590346
Sinusitis	23.95	17.99	207	131546	195294	79417341
Gastrointestinal disorder	23.94	17.99	112	131641	122093	79490542
Lip pain	23.73	17.99	23	131730	2104	79610531
Tongue blistering	23.57	17.99	20	131733	1539	79611096
Haemoptysis	23.51	17.99	35	131718	55964	79556671
Nephropathy toxic	23.48	17.99	3	131750	20416	79592219
Muscle twitching	23.40	17.99	6	131747	24758	79587877
Metastases to retroperitoneum	23.34	17.99	12	131741	392	79612243
Grip strength decreased	23.33	17.99	4	131749	21865	79590770
Joint range of motion decreased	23.25	17.99	13	131740	33269	79579366
Hepatitis	23.23	17.99	35	131718	55692	79556943
Paraesthesia	23.23	17.99	415	131338	175908	79436727
Epilepsy	23.19	17.99	20	131733	40840	79571795
Muscle spasms	22.93	17.99	411	131342	174319	79438316
Cerebral infarction	22.86	17.99	25	131728	45651	79566984
Metastases to lymph nodes	22.78	17.99	52	131701	10345	79602290
Tongue discomfort	22.74	17.99	24	131729	2429	79610206
Noninfective gingivitis	22.73	17.99	20	131733	1616	79611019
Infusion site coldness	22.71	17.99	10	131743	229	79612406
Peritonitis	22.58	17.99	9	131744	28027	79584608
Eructation	22.19	17.99	53	131700	10856	79601779
Agranulocytosis	22.14	17.99	25	131728	45005	79567630
Cyanosis	22.13	17.99	7	131746	25175	79587460
Dental discomfort	22.12	17.99	12	131741	438	79612197
Radiation injury	22.05	17.99	15	131738	828	79611807
Cholelithiasis	22.03	17.99	33	131720	52631	79560004
Ataxia	21.94	17.99	7	131746	25032	79587603
Aphasia	21.85	17.99	27	131726	46705	79565930
Joint neoplasm	21.84	17.99	7	131746	63	79612572
Nail discolouration	21.83	17.99	26	131727	3005	79609630
Neuroendocrine breast tumour	21.74	17.99	6	131747	30	79612605
Splenomegaly	21.70	17.99	4	131749	20750	79591885
Metastases to eye	21.65	17.99	10	131743	257	79612378
Hallucination, auditory	21.61	17.99	4	131749	20689	79591946
Product packaging issue	21.11	17.99	17	131736	1216	79611419
Gingival bleeding	21.06	17.99	67	131686	16209	79596426
Atrial flutter	20.90	17.99	5	131748	21620	79591015
Hypothyroidism	20.80	17.99	34	131719	52358	79560277
Nail avulsion	20.75	17.99	8	131745	129	79612506
Hyperaesthesia teeth	20.66	17.99	20	131733	1826	79610809
Oral herpes	20.60	17.99	95	131658	27359	79585276
Tooth disorder	20.60	17.99	92	131661	26141	79586494
Dialysis	20.55	17.99	3	131750	18459	79594176
Cardiomegaly	20.36	17.99	9	131744	26343	79586292
Inappropriate antidiuretic hormone secretion	20.30	17.99	9	131744	26304	79586331
Electrolyte imbalance	20.25	17.99	13	131740	30868	79581767
Mania	20.25	17.99	3	131750	18257	79594378
Feeding disorder	20.21	17.99	66	131687	16188	79596447
Acute coronary syndrome	20.20	17.99	5	131748	21128	79591507
Metastases to spine	20.19	17.99	30	131723	4294	79608341
Ileus	20.17	17.99	9	131744	26202	79586433
Metastases to kidney	20.00	17.99	12	131741	532	79612103
Soft tissue neoplasm	19.96	17.99	7	131746	85	79612550
Bacteraemia	19.96	17.99	15	131738	32809	79579826
Pulmonary arterial hypertension	19.93	17.99	11	131742	28355	79584280
Joint effusion	19.88	17.99	3	131750	18011	79594624
Skin sensitisation	19.81	17.99	15	131738	980	79611655
Neutropenic sepsis	19.74	17.99	10	131743	27054	79585581
Hypertensive crisis	19.69	17.99	5	131748	20765	79591870
Bone lesion	19.41	17.99	35	131718	5884	79606751
Hypovolaemia	19.40	17.99	3	131750	17688	79594947
Hypogeusia	19.27	17.99	19	131734	1775	79610860
Metastases to spinal cord	19.13	17.99	6	131747	50	79612585
Breast cancer	19.12	17.99	108	131645	33673	79578962
Acute myeloid leukaemia	18.93	17.99	14	131739	30871	79581764
Haematemesis	18.86	17.99	36	131717	52228	79560407
Aspiration	18.83	17.99	5	131748	20153	79592482
Foreign body in throat	18.74	17.99	11	131742	468	79612167
Metastases to the mediastinum	18.73	17.99	12	131741	598	79612037
Tumour pain	18.71	17.99	21	131732	2278	79610357
Post procedural complication	18.63	17.99	8	131745	23821	79588814
Tumour marker decreased	18.62	17.99	6	131747	55	79612580
Supraventricular tachycardia	18.54	17.99	6	131747	21264	79591371
Tongue disorder	18.52	17.99	58	131695	13917	79598718
Joint dislocation	18.29	17.99	3	131750	16936	79595699
Gamma-glutamyltransferase decreased	18.21	17.99	10	131743	374	79612261
Psychomotor hyperactivity	18.16	17.99	3	131750	16846	79595789
Uveitis	18.13	17.99	3	131750	16827	79595808
Acute cutaneous lupus erythematosus	18.02	17.99	10	131743	382	79612253

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01EF01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Cyclin-dependent kinase (CDK) inhibitors
FDA MoA	N0000175082	Kinase Inhibitors
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D047428	Protein Kinase Inhibitors
FDA EPC	N0000175605	Kinase Inhibitor
FDA MoA	N0000190114	Cytochrome P450 3A Inhibitors
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:82665	EC 2.7.11.22 (cyclin-dependent kinase) inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hormone receptor positive malignant neoplasm of breast	indication	417181009
Human epidermal growth factor 2 negative carcinoma of breast	indication	431396003

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.03	Basic
pKa2	7.08	Basic
pKa3	5.81	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
100MG	IBRANCE	PFIZER	N207103	Feb. 3, 2015	RX	CAPSULE	ORAL	7456168	Jan. 16, 2023	PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY IN POSTMENOPAUSAL WOMEN OR MEN, OR WITH FULVESTRANT IN PTS WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
100MG	IBRANCE	PFIZER	N207103	Feb. 3, 2015	RX	CAPSULE	ORAL	7456168	Jan. 16, 2023	PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR IN PTS AS INITIAL ENDOCRINE-BASED THERAPY OR WITH FULVESTRANT WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
100MG	IBRANCE	PFIZER	N207103	Feb. 3, 2015	RX	CAPSULE	ORAL	7456168	Jan. 16, 2023	TREATING HR-POS., HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER WITH PALBOCICLIB IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE BASED THERAPY IN POSTMENOPAUSAL WOMEN OR FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
125MG	IBRANCE	PFIZER	N207103	Feb. 3, 2015	RX	CAPSULE	ORAL	7456168	Jan. 16, 2023	PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY IN POSTMENOPAUSAL WOMEN OR MEN, OR WITH FULVESTRANT IN PTS WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
125MG	IBRANCE	PFIZER	N207103	Feb. 3, 2015	RX	CAPSULE	ORAL	7456168	Jan. 16, 2023	PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR IN PTS AS INITIAL ENDOCRINE-BASED THERAPY OR WITH FULVESTRANT WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
125MG	IBRANCE	PFIZER	N207103	Feb. 3, 2015	RX	CAPSULE	ORAL	7456168	Jan. 16, 2023	TREATING HR-POS., HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER WITH PALBOCICLIB IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE BASED THERAPY IN POSTMENOPAUSAL WOMEN OR FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
75MG	IBRANCE	PFIZER	N207103	Feb. 3, 2015	RX	CAPSULE	ORAL	7456168	Jan. 16, 2023	PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY IN POSTMENOPAUSAL WOMEN OR MEN, OR WITH FULVESTRANT IN PTS WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
75MG	IBRANCE	PFIZER	N207103	Feb. 3, 2015	RX	CAPSULE	ORAL	7456168	Jan. 16, 2023	PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR IN PTS AS INITIAL ENDOCRINE-BASED THERAPY OR WITH FULVESTRANT WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
75MG	IBRANCE	PFIZER	N207103	Feb. 3, 2015	RX	CAPSULE	ORAL	7456168	Jan. 16, 2023	TREATING HR-POS., HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER WITH PALBOCICLIB IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE BASED THERAPY IN POSTMENOPAUSAL WOMEN OR FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
100MG	IBRANCE	PFIZER	N212436	Nov. 1, 2019	RX	TABLET	ORAL	7456168	Jan. 16, 2023	PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY IN POSTMENOPAUSAL WOMEN OR MEN, OR WITH FULVESTRANT IN PTS WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
100MG	IBRANCE	PFIZER	N212436	Nov. 1, 2019	RX	TABLET	ORAL	7456168	Jan. 16, 2023	PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR IN PTS AS INITIAL ENDOCRINE-BASED THERAPY OR WITH FULVESTRANT WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
125MG	IBRANCE	PFIZER	N212436	Nov. 1, 2019	RX	TABLET	ORAL	7456168	Jan. 16, 2023	PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY IN POSTMENOPAUSAL WOMEN OR MEN, OR WITH FULVESTRANT IN PTS WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
125MG	IBRANCE	PFIZER	N212436	Nov. 1, 2019	RX	TABLET	ORAL	7456168	Jan. 16, 2023	PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR IN PTS AS INITIAL ENDOCRINE-BASED THERAPY OR WITH FULVESTRANT WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
75MG	IBRANCE	PFIZER	N212436	Nov. 1, 2019	RX	TABLET	ORAL	7456168	Jan. 16, 2023	PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY IN POSTMENOPAUSAL WOMEN OR MEN, OR WITH FULVESTRANT IN PTS WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
75MG	IBRANCE	PFIZER	N212436	Nov. 1, 2019	RX	TABLET	ORAL	7456168	Jan. 16, 2023	PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR IN PTS AS INITIAL ENDOCRINE-BASED THERAPY OR WITH FULVESTRANT WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Cyclin-dependent kinase 6	Kinase	Q00534	CDK6_HUMAN	INHIBITOR	IC50	7.82		SCIENTIFIC LITERATURE	DRUG LABEL
Cyclin-dependent kinase 4	Kinase	P11802	CDK4_HUMAN	INHIBITOR	IC50	7.96		SCIENTIFIC LITERATURE	DRUG LABEL
AP2-associated protein kinase 1	Kinase	Q2M2I8	AAK1_HUMAN		Kd	5.38		CHEMBL
Serine/threonine-protein kinase 16	Kinase	O75716	STK16_HUMAN		Kd	5		CHEMBL
BMP-2-inducible protein kinase	Kinase	Q9NSY1	BMP2K_HUMAN		Kd	4.58		CHEMBL
Dual specificity protein kinase CLK1	Kinase	P49759	CLK1_HUMAN		Kd	6.56		CHEMBL
Cyclin-dependent kinase 16	Kinase	Q00536	CDK16_HUMAN		Kd	5.56		CHEMBL
Mitogen-activated protein kinase 9	Kinase	P45984	MK09_HUMAN		Kd	5.54		CHEMBL
Cyclin-dependent kinase 9	Kinase	P50750	CDK9_HUMAN		IC50	6.10		CHEMBL
Cyclin-dependent kinase 17	Kinase	Q00537	CDK17_HUMAN		Kd	5.90		CHEMBL
Casein kinase II subunit alpha'	Kinase	P19784	CSK22_HUMAN		Kd	6.31		CHEMBL
Dual specificity mitogen-activated protein kinase kinase 4	Kinase	P45985	MP2K4_HUMAN		Kd	5.90		CHEMBL
Serine/threonine-protein kinase D2	Kinase	Q9BZL6	KPCD2_HUMAN		Kd	5.25		CHEMBL
Tyrosine-protein kinase JAK3	Kinase	P52333	JAK3_HUMAN		IC50	7.20		CHEMBL
Serine/threonine-protein kinase TAO3	Kinase	Q9H2K8	TAOK3_HUMAN		Kd	4.80		CHEMBL
Serine/threonine-protein kinase TAO2	Kinase	Q9UL54	TAOK2_HUMAN		Kd	4.55		CHEMBL
Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma	Kinase	Q8TBX8	PI42C_HUMAN		Kd	5.76		CHEMBL
Cyclin-dependent kinase 4/cyclin D1	Kinase	P11802 P24385	CDK4_HUMAN CCND1_HUMAN		IC50	8.70		CHEMBL
CDK2/Cyclin A	Kinase	P20248 P24941	CCNA2_HUMAN CDK2_HUMAN		IC50	6.64		CHEMBL
CDK6/cyclin D1	Kinase	P24385 Q00534	CCND1_HUMAN CDK6_HUMAN		IC50	8.42		CHEMBL
Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Kinase	P48426	PI42A_HUMAN		Kd	6.68		CHEMBL
Uncharacterized protein FLJ45252	Unclassified	Q6ZSR9	YJ005_HUMAN		Kd	4.56		CHEMBL
Ribosomal protein S6 kinase alpha-1	Kinase	Q15418	KS6A1_HUMAN	INHIBITOR	IC50	5.10		SCIENTIFIC LITERATURE
Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Kinase	Q13627	DYR1A_HUMAN	INHIBITOR	IC50	5.70		SCIENTIFIC LITERATURE
Serine/threonine-protein kinase D3	Kinase	O94806	KPCD3_HUMAN		Kd	4.79		CHEMBL
Receptor-type tyrosine-protein kinase FLT3	Kinase	P36888	FLT3_HUMAN		IC50	5.46		CHEMBL

External reference:

ID	Source
G9ZF61LE7G	UNII
D10372	KEGG_DRUG
4034136	VUID
N0000191426	NUI
827022-33-3	SECONDARY_CAS_RN
4034136	VANDF
C3853822	UMLSCUI
CHEBI:85993	CHEBI
LQQ	PDB_CHEM_ID
CHEMBL189963	ChEMBL_ID
5330286	PUBCHEM_CID
DB09073	DRUGBANK_ID
CHEMBL2364621	ChEMBL_ID
9802	INN_ID
C500026	MESH_SUPPLEMENTAL_RECORD_UI
7380	IUPHAR_LIGAND_ID
1601374	RXNORM
232484	MMSL
30872	MMSL
d08342	MMSL
015881	NDDF
715958001	SNOMEDCT_US
763549001	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Ibrance	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0187	CAPSULE	75 mg	ORAL	NDA	29 sections
Ibrance	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0187	CAPSULE	75 mg	ORAL	NDA	29 sections
Ibrance	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0188	CAPSULE	100 mg	ORAL	NDA	29 sections
Ibrance	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0188	CAPSULE	100 mg	ORAL	NDA	29 sections
Ibrance	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0189	CAPSULE	125 mg	ORAL	NDA	29 sections
Ibrance	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0189	CAPSULE	125 mg	ORAL	NDA	29 sections
Ibrance	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0284	TABLET, FILM COATED	75 mg	ORAL	NDA	33 sections
Ibrance	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0284	TABLET, FILM COATED	75 mg	ORAL	NDA	33 sections
Ibrance	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0486	TABLET, FILM COATED	100 mg	ORAL	NDA	33 sections
Ibrance	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0486	TABLET, FILM COATED	100 mg	ORAL	NDA	33 sections
Ibrance	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0688	TABLET, FILM COATED	125 mg	ORAL	NDA	33 sections
Ibrance	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0688	TABLET, FILM COATED	125 mg	ORAL	NDA	33 sections
Ibrance	HUMAN PRESCRIPTION DRUG LABEL	1	63539-187	CAPSULE	75 mg	ORAL	NDA	33 sections
Ibrance	HUMAN PRESCRIPTION DRUG LABEL	1	63539-187	CAPSULE	75 mg	ORAL	NDA	33 sections
Ibrance	HUMAN PRESCRIPTION DRUG LABEL	1	63539-188	CAPSULE	100 mg	ORAL	NDA	33 sections
Ibrance	HUMAN PRESCRIPTION DRUG LABEL	1	63539-188	CAPSULE	100 mg	ORAL	NDA	33 sections
Ibrance	HUMAN PRESCRIPTION DRUG LABEL	1	63539-189	CAPSULE	125 mg	ORAL	NDA	33 sections
Ibrance	HUMAN PRESCRIPTION DRUG LABEL	1	63539-189	CAPSULE	125 mg	ORAL	NDA	33 sections
Ibrance	HUMAN PRESCRIPTION DRUG LABEL	1	63539-284	TABLET, FILM COATED	75 mg	ORAL	NDA	32 sections
Ibrance	HUMAN PRESCRIPTION DRUG LABEL	1	63539-284	TABLET, FILM COATED	75 mg	ORAL	NDA	32 sections
Ibrance	HUMAN PRESCRIPTION DRUG LABEL	1	63539-486	TABLET, FILM COATED	100 mg	ORAL	NDA	32 sections
Ibrance	HUMAN PRESCRIPTION DRUG LABEL	1	63539-486	TABLET, FILM COATED	100 mg	ORAL	NDA	32 sections
Ibrance	HUMAN PRESCRIPTION DRUG LABEL	1	63539-688	TABLET, FILM COATED	125 mg	ORAL	NDA	32 sections
Ibrance	HUMAN PRESCRIPTION DRUG LABEL	1	63539-688	TABLET, FILM COATED	125 mg	ORAL	NDA	32 sections